Drug intelligence / Profile preview

RCells

Development stage: Preclinical
Lead developer: ReproGO
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

RCells is an induced pluripotent stem cell (iPSC)-derived vasculogenic cell therapy being developed by ReproGO. The therapy consists of iPSC-derived endothelial and vascular cells designed to promote vasculogenesis and revascularization in ischemic tissues. It is primarily targeted at treating ischemic diseases and chronic wounds, including critical limb ischemia (CLI), diabetic foot ulcers (DFU), and pressure ulcers. By providing a source of functional vascular cells, RCells aims to restore blood flow and facilitate healing in conditions where endogenous repair mechanisms are insufficient. The program is currently in the preclinical stage of development.

Brand names: RCells
Other names: iPSC-derived vasculogenic cell therapyiPSC-derived endothelial/vascular cells

Beyond the preview

Go deeper on RCells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCells.

Explore the full profile